Compare eye surgery plus peeling versus anti-VEGF injections
Part of Eyes & vision, Hormones & metabolism clinical trials.
This trial compares a minimally invasive eye procedure (vitrectomy with peeling) versus anti-VEGF injections to treat new diabetic macular edema in people who have not had treatment yet. It looks at which option improves vision and eye swelling for people with diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have type 1 or type 2 diabetes
- Have a recent HbA1c under 10% (blood sugar control) within 3 months
- Have new (treatment-naïve) diabetic macular edema diagnosed within the last 12 months
- Have specific eye findings on scans: thick central swelling (CST over 300 microns) and fluid seen on OCT
- Not have had any prior treatment for macular edema (no anti-VEGF shots, steroid eye injections, or laser treatment)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This study tests whether receiving anti-VEGF injections for diabetic macular edema (DME) at home is as safe and effective as getting them in the hospital. You would use a home device to check your vision and eye scans, and a nurse would visit for injections.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This study tests whether a new drug (AVT29) is as safe and effective as the standard treatment Eylea HD for people with diabetic macular edema (DME) — a condition where fluid builds up in the back of the eye due to diabetes. If you have vision loss from DME and haven't had anti-VEGF injections before, you may be able to join.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.